“Hope on the Horizon” for Alzheimer’s as New Drug Trials Offer Fresh Optimism
A new review shows a rise in the number of potential drugs that could treat or prevent Alzheimer's disease.
There’s fresh hope for people living with Alzheimer’s as a new review reveals a surge in potential treatments being trialled – and one Blackpool woman says it could be life-changing.
A total of 138 drugs are currently being tested in 182 clinical trials around the world, with researchers saying we’re at a “tipping point” in dementia research.
Among the most promising developments are repurposed drugs – medications already used for other conditions like diabetes and high cholesterol – now being trialled to slow or even prevent Alzheimer’s. One of those is semaglutide, the key ingredient in the popular weight-loss drug Ozempic, which is now being tested for its effects on early-stage dementia.
“It’s exciting – but we need to see results”
For Blackpool local,Gail Gregory, the news brings cautious optimism. Gail was diagnosed with young-onset dementia in 2019 and has been sharing her journey through her blog, Too Young For Dementia.
“It’s always exciting to hear that there’s something new that could possibly help anybody living with dementia or Alzheimer’s,” she said.
“But it’s been said so many times before. Until it’s actually approved, it’s like – seeing is believing.”
Gail says the growing number of people being diagnosed every day makes the need for early intervention more urgent than ever.
“It’s not getting any better – it’s getting worse. There’s more and more people diagnosed every single day, and it’s not an easy disease to cope with.
“We do lack the support out there. So to find something would be life-changing.”
A growing pipeline of hope
The review, published in the journal Alzheimer’s and Dementia: Translational Research and Clinical Interventions, shows an 11% increase in trials compared to last year. Experts say the variety of drugs being tested – including those targeting different stages and types of dementia – is a major breakthrough.
Dr Sheona Scales from Alzheimer’s Research UK said:
“This year has really given us real cause for optimism. The pipeline of drug development is growing, it’s diversifying and accelerating.”
Meanwhile, Dr Emma Mead from the Oxford Drug Discovery Institute called it a “tipping point” in dementia research, adding that repurposing existing drugs could speed up progress dramatically.
What’s next?
Two drugs – lecanemab and donanemab – have already shown promise in treating early Alzheimer’s, but are still under review by UK regulators for NHS use. Experts say these are just the beginning.
Professor James Rowe, a neurologist at the University of Cambridge, said:
“What strikes me is not just the number of new drugs, but their range. We’re seeing multiple shots on goal.”
And for people like Gail, that goal is simple:
“If we could find an early intervention, just think – it would help the health service too. It’s a win-win.”